--- title: "Semaglutide: what sources report" url: https://humanpeptides.fyi/peptides/semaglutide site: humanpeptides.fyi last_reviewed: 2026-10-11 --- # Semaglutide > humanpeptides.fyi makes no claims of its own. Every statement below reports what a cited source says, with its link. Not medical advice. Semaglutide: Long-acting GLP-1 receptor agonist (Novo Nordisk) that reduces appetite and improves glucose control. The sources cited here most often discuss it for: About 15% weight loss; Fewer heart attacks and strokes; Kidney and liver protection. Evidence label: Approved (specific use). ## At a glance - **Type:** Peptide - **Family:** Weight & Metabolic - **Evidence label:** Approved (specific use) (5 of 5) - **Regulatory status:** FDA warns that compounded and other unapproved versions of semaglutide do not undergo FDA review for safety, effectiveness or quality before they are marketed, and that counterfeit Ozempic has been marketed in the US. - **Goals discussed:** Fat Loss & Metabolism, Heart, Liver & Kidney - **Also called:** Ozempic, Wegovy, Rybelsus, semaglutide sodium, semaglutide acetate, skinny jab, weight-loss jabs, Ozempic face - **Last reviewed:** 2026-10-11 ## What is Semaglutide? - Long-acting GLP-1 receptor agonist (Novo Nordisk) that reduces appetite and improves glucose control; FDA-approved as Ozempic/Rybelsus (type 2 diabetes) and Wegovy (chronic weight management, cardiovascular risk reduction, and MASH with fibrosis since Aug 2025). Sources: , **Regulatory status:** FDA warns that compounded and other unapproved versions of semaglutide do not undergo FDA review for safety, effectiveness or quality before they are marketed, and that counterfeit Ozempic has been marketed in the US. Source: ## What is Semaglutide researched for? ### 1. About 15% weight loss - Weight loss: STEP 1 (68 wk) mean 14.9% vs 2.4% placebo with 2.4 mg weekly (human phase 3 RCT) Sources: , - Goals: [Fat Loss & Metabolism](https://humanpeptides.fyi/objectives/fat-loss) ### 2. Fewer heart attacks and strokes - Cardiovascular protection: SELECT trial cut major adverse cardiovascular events 20% (HR 0.80) in people with obesity and heart disease without diabetes (human phase 3 RCT) Sources: , - Goals: [Heart, Liver & Kidney](https://humanpeptides.fyi/objectives/organs) ### 3. Kidney and liver protection - Kidney protection: FLOW trial reduced major kidney outcomes 24% and slowed eGFR decline in type 2 diabetes + CKD, also lowering CV events and death (human RCT) - Liver: accelerated FDA approval for MASH with F2-F3 fibrosis - Sources for this benefit: , - Goals: [Heart, Liver & Kidney](https://humanpeptides.fyi/objectives/organs) ## What do researchers and users say about Semaglutide? > "The term “Ozempic® face” has been coined to describe the exaggerated volume loss from semaglutide therapy, resulting in advanced facial aging." > > Daneshgaran G, et al., "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions (2025). Context: Background sentence of a systematic review of 23 plastic surgery papers plus Google Trends data; low level of evidence. > "FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products." > > US Food and Drug Administration, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Context: FDA safety communication about compounded and unapproved semaglutide, not the approved branded products. > "I'm 37 and lost about 53 lbs on Wegovy. I'm really happy with the weight loss, but my face changed much more than I expected." > > Anonymous user, r/Semaglutide, What to do about Ozempic face. Context: Single forum self-report; the user later attributed the change to rapid weight loss rather than the medicine itself. ## What side effects of Semaglutide are reported? - Boxed warning: thyroid C-cell tumors (rodent data), contraindicated with personal/family MTC or MEN2; warnings for acute pancreatitis and gallbladder disease; GI side effects (nausea, vomiting, diarrhea, constipation) most common (FDA label) Sources: - Lean-mass loss alongside fat Sources: - Non-arteritic anterior ischemic optic neuropathy (NAION), sudden loss of vision from reduced blood flow to the optic nerve; classed as very rare, up to 1 in 10,000 users. (EMA safety review) Sources: - Pulmonary aspiration (inhaling stomach contents) during general anesthesia or deep sedation; patients should tell clinicians about planned procedures. (FDA label) Sources: - Suicidal behavior and ideation: label advises monitoring for depression or suicidal thoughts and stopping if they develop. (FDA label) Sources: - Acute kidney injury from fluid loss (volume depletion), for example after vomiting or diarrhea. (FDA label) Sources: - Diabetic retinopathy complications in people with type 2 diabetes, and an increase in resting heart rate that the label says to monitor. (FDA label) Sources: - Serious allergic reactions including anaphylaxis and angioedema reported after marketing. (FDA label) Sources: - May cause fetal harm; because of its long half-life the label advises stopping at least 2 months before a planned pregnancy. (FDA label) Sources: - Hospitalizations linked to measuring errors with compounded semaglutide, plus counterfeit Ozempic in the US supply that may contain the wrong ingredient or amount. (FDA safety communication) Sources: ## What do peptide guides say about Semaglutide? - **Dr. Axe:** Dr. Axe's library lists semaglutide as FDA-approved only in specific formulations for labeled uses, stresses that compounded products are not FDA-approved, and highlights the thyroid C-cell tumor boxed warning. - **PepEdHub:** PepEdHub explains that semaglutide shares 94% of its structure with natural GLP-1, and a fatty acid side chain that binds albumin stretches its half-life to about a week. - **Seek Peptides:** Seek Peptides' complete peptide list picks semaglutide as the best weight-loss option for most people, citing its effectiveness, cost and the depth of its safety data compared with research peptides. - **NCBI PMC:** A 2025 review notes that one year after stopping semaglutide, trial participants regained about two-thirds of the weight they had lost and their cardiometabolic improvements returned to baseline. - **European Medicines Agency:** EMA's safety committee found semaglutide roughly doubles the risk of NAION, a vision-threatening optic nerve condition, in adults with type 2 diabetes, about one extra case per 10,000 person-years. ## What does the research say, system by system? ### Body & tissues - Heart/vessels (SELECT), kidney (FLOW), liver (MASH approval), visceral fat reduction Sources: , , ### Hormones & physiology - GLP-1 receptor agonism: glucose-dependent insulin secretion, appetite suppression, slowed gastric emptying (FDA label) Sources: ### Brain, mood & sleep - Alzheimer's: evoke/evoke+ phase 3 (n=3,808) oral semaglutide did NOT slow cognitive decline (human RCT, negative) Sources: , ### Weight & metabolism - ~15% weight loss at 68 weeks; total fat mass -19.3% and visceral fat reduced (human RCT/DXA substudy) Sources: , ### Muscle - STEP 1 DXA substudy: lean mass fell 9.7% in absolute terms, though lean proportion of body mass rose ~3 points because fat fell more; DXA lean mass is not purely muscle (human RCT substudy) Sources: ### Also notable - Basis for cagrilintide combo (CagriSema ~20% weight loss) Sources: - Compounded semaglutide carries distinct adverse-event signals in FAERS analysis (cited in pharmacy review) Sources: ## How strong is the evidence for Semaglutide? **Approved (specific use)** (5 of 5). FDA-approved; strong human phase 3 RCT and outcomes data _Approved by the FDA (or a major regulator) for at least one specific use. Approval covers that use only, not the other benefits listed._ ## Street names and stacks - Street names: [Sema / The Skinny Shot](https://humanpeptides.fyi/street-names#nick-sema) ## Questions about Semaglutide ### What is Semaglutide? Long-acting GLP-1 receptor agonist (Novo Nordisk) that reduces appetite and improves glucose control. ### Is Semaglutide FDA-approved? FDA warns that compounded and other unapproved versions of semaglutide do not undergo FDA review for safety, effectiveness or quality before they are marketed, and that counterfeit Ozempic has been marketed in the US. ### What is Semaglutide researched for? The sources cited on this page most often discuss three outcomes: About 15% weight loss; Fewer heart attacks and strokes; Kidney and liver protection. Each line above shows what the source reports and how strong that evidence is. ### What side effects of Semaglutide are reported? Reported in the cited sources: Boxed warning: thyroid C-cell tumors (rodent data), contraindicated with personal/family MTC or MEN2; warnings for acute pancreatitis and gallbladder disease; GI side effects (nausea, vomiting, diarrhea, constipation) most common; Lean-mass loss alongside fat; Non-arteritic anterior ischemic optic neuropathy (NAION), sudden loss of vision from reduced blood flow to the optic nerve; classed as very rare, up to 1 in 10,000 users. The list is not complete, and few listed risks does not mean a compound is safe. ### How strong is the evidence for Semaglutide? Evidence label: Approved (specific use). FDA-approved; strong human phase 3 RCT and outcomes data. ### What else is Semaglutide called? Names used for it include Ozempic, Wegovy, Rybelsus, semaglutide sodium, semaglutide acetate, skinny jab, weight-loss jabs, Ozempic face. ### Does humanpeptides.fyi recommend Semaglutide? No. humanpeptides.fyi makes no claims and no recommendations of its own. It summarizes and links to what others have published and posted. Nothing here is medical advice; talk to a licensed clinician. --- Family: [Weight & Metabolic](https://humanpeptides.fyi/peptides?cat=metabolic). HTML version: . Disclaimer: